ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Aflibercept (Eyluxvi)

Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual… Show the full indication

Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). 

Biosimilar
CHMP opinion 24 Jul 2025 → EU licence 15 Sept 2025 · Biolitec pharma Limited Zweigniederlassung Jena
EU · EU licence (European Commission)

Aflibercept (Mynzepli)

Mynzepli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),- visual impairment due to diabetic macular oedema (DME),- visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Biosimilar
CHMP opinion 19 Jun 2025 → EU licence 18 Aug 2025 · Advanz Pharma Limited
EU · EU licence (European Commission)

Aflibercept (Afiveg)

Afiveg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section1), visual impairment… Show the full indication

Afiveg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).

Biosimilar
CHMP opinion 19 Jun 2025 → EU licence 18 Aug 2025 · STADA Arzneimittel AG
EU · EU licence (European Commission)

Aflibercept (Vgenfli)

Vgenfli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),- visual impairment due to diabetic macular oedema (DME),- visual impairment due to myopic choroidal neovascularisation (myopic CNV).

Biosimilar
CHMP opinion 19 Jun 2025 → EU licence 14 Aug 2025 · Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
EU · EU licence (European Commission)

Aflibercept (Eiyzey)

Eiyzey is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual… Show the full indication

Eiyzey is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1)s.

Biosimilar
CHMP opinion 19 Jun 2025 → EU licence 14 Aug 2025 · Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
EU · EU licence (European Commission)

Aflibercept (Eydenzelt)

Eydenzelt is indicated for adults for the treatment of: neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual… Show the full indication

Eydenzelt is indicated for adults for the treatment of: neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).

Biosimilar
CHMP opinion 12 Dec 2024 → EU licence 12 Feb 2025 · Celltrion Healthcare Hungary Kft.

Research

Neonatology · Neonatology · 2026-01-08

Prespecified 3-year interim analysis of an RCT of aflibercept 0.4 mg vs laser for retinopathy of prematurity (100 children, 90 analysed): most had no ROP or unfavourable structural outcomes (98.3% and 93.9% vs 96.7% and 94.1%); high myopia 8.9% vs 24.1% of eyes.

RCTn = 100
Stahl et al. Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.